American Society of Hematology

Fig. 5.

$Fig. 5. Immune response to bovine protein and retroviral envelope. / (A) Ouchterlony gel of sera from patient 2 at various protocol days. Patient sera (center well); FCS, neat (well no. 1), diluted 1:4 (well no. 2), and 1:8 (well no. 3); bovine serum albumin neat (well no. 4), diluted 1:4 (well no. 5), and 1:8 (well no. 6). (B) Ouchterlony gel of sera from patient 2 (center well), bovine lipoprotein (well no. 1), FCS (well no. 2), lipoprotein-deficient bovine sera (well no. 3), bovine α-2 macroglobulin (well no. 4), bovine ceruloplasmin (well no. 5), Cohn fractions II/III containing primarily β and γ globulins (well no. 6). (C) Western blot assay of patients' sera obtained at various time points to detect antiretroviral antibodies. Each blot begins with a positive monkey serum control (+), followed by molecular weight markers (M) and then a control negative monkey serum (−).$

Immune response to bovine protein and retroviral envelope.

(A) Ouchterlony gel of sera from patient 2 at various protocol days. Patient sera (center well); FCS, neat (well no. 1), diluted 1:4 (well no. 2), and 1:8 (well no. 3); bovine serum albumin neat (well no. 4), diluted 1:4 (well no. 5), and 1:8 (well no. 6). (B) Ouchterlony gel of sera from patient 2 (center well), bovine lipoprotein (well no. 1), FCS (well no. 2), lipoprotein-deficient bovine sera (well no. 3), bovine α-2 macroglobulin (well no. 4), bovine ceruloplasmin (well no. 5), Cohn fractions II/III containing primarily β and γ globulins (well no. 6). (C) Western blot assay of patients' sera obtained at various time points to detect antiretroviral antibodies. Each blot begins with a positive monkey serum control (+), followed by molecular weight markers (M) and then a control negative monkey serum (−).

This Feature Is Available To Subscribers Only